<DOC>
	<DOCNO>NCT02002767</DOCNO>
	<brief_summary>This study evaluate single-dose pharmacokinetics ( PK ) , safety , tolerability GS-5816 participant severe renal impairment use match healthy participant control group .</brief_summary>
	<brief_title>Pharmacokinetics GS-5816 Subjects With Normal Renal Function Severe Renal Impairment</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Renal Insufficiency</mesh_term>
	<criteria>General good health stable chronic kidney disease Severe Renal Impairment Group Screening lab within define threshold Creatinine clearance must &lt; 30 mL/min Severe Renal Impairment group , â‰¥ 90 mL/min Normal Renal Function group Females pregnant nursing , male pregnant partner Infection hepatitis B virus ( HBV ) , hepatitis C virus ( HCV ) HIV History clinically significant illness ( include psychiatric cardiac ) medical disorder may interfere subject treatment and/or adherence protocol</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>79 Years</maximum_age>
	<verification_date>June 2014</verification_date>
</DOC>